Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | M3T01 |
| Synonyms | |
| Therapy Description |
Limited information is currently available on M3T01, a putative monoclonal antibody targeting FasL (Dec 2024). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| M3T01 | M 3T01|M-3T01 | Limited information is currently available on M3T01, a putative monoclonal antibody targeting FasL (Dec 2024). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT06719362 | Phase I | M3T01 M3T01 + Temozolomide M3T01 + Pembrolizumab Fluorouracil + Leucovorin + M3T01 + Oxaliplatin + Pembrolizumab | A Clinical Trial to Evaluate the Safety, Tolerability and Clinical Efficacy of M3T01 Monotherapy and in Combination With Pembrolizumab and Other Systemic Therapies | Recruiting | USA | 0 |